GlassScriptPhysician profile
Amanda Chandler
NPI 1750069449
$3,236.93
in general payments reported to CMS, 2019-2025
20 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $525 · 2024: $973 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,153 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,152.93 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $919.45 | 2023-2025 | |
| Gilead Sciences, INC. | $524.56 | 2023-2025 | Epclusa, Livdelzi |
| Janssen Biotech, INC. | $412.03 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $377.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.49 | 2023-2024 | Trulance, Relistor, Xifaxan |
| Phathom Pharmaceuticals, INC. | $162.65 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $157.15 | 2023-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $134.95 | 2024-2025 | Entyvio |
| Pfizer INC. | $67.69 | 2023-2024 | |
| Ardelyx, INC. | $58.97 | 2023-2025 | Ibsrela |
| United Therapeutics Corporation | $27.77 | 2025 | Remodulin, Orenitram |
| Shield Therapeutics INC | $20.54 | 2024 | |
| Grifols USA, LLC | $20.23 | 2024 | Prolastin-C Liquid |
| Genzyme Corporation | $20.20 | 2023 | |
| Corcept Therapeutics | $20.18 | 2024 | Korlym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.16 | 2025 | Ofev |
| Radius Health, INC. | $17.77 | 2025 | Tymlos |
| Merck Sharp & Dohme LLC | $16.26 | 2024 | Dificid |
| Exact Sciences Corporation | $16.25 | 2023 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $13.50 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.